11.09.2020 • NewsAbbVie

AbbVie and I-Mab in Cancer Collaboration

US biopharma AbbVie has signed a global collaboration agreement with China’s I-Mab to develop and commercialize lemzoparlimab – also known as TJC4 – an anti-CD47 monoclonal antibody for treating multiple cancers. The companies can also potentially expand the collaboration to include other therapies.

“The addition of I-Mab's novel CD47 programs complements our global clinical strategy in hematology and immuno-oncology,” said Thomas Hudson, AbbVie’s senior vice president of R&D and chief scientific officer. In a recent phase 1 clinical trial, lemzoparlimab showed promising results relating to drug safety and a more favorable pharmacokinetics profile in cancer patients.

Under the terms of the agreement, AbbVie will pay $180 million upfront to I-Mab for exclusive global rights (excluding greater China) to lemzoparlimab as well as a milestone payment of $20 million for the positive results from the Phase 1 trial. The Chinese biotech will be responsible for developing and commercializing lemzoparlimab in mainland China, Macau and Hong Kong.

I-Mab will also be entitled to earn up to $840 million in future success-based clinical and development milestones as well as up to $900 million in commercial milestones and tiered low-to-mid-teen royalties on net sales.

 

Author: Elaine Burridge, Freelance Journalist

AbbVie has signed a global collaboration agreement with China’s I-Mab to...
AbbVie has signed a global collaboration agreement with China’s I-Mab to commercialize lemzoparlimab – also known as TJC4 – an anti-CD47 monoclonal antibody for treating multiple cancers. The companies can also potentially expand the collaboration to include other therapies. (c) AbbVie

Company

Logo:

AbbVie Inc.


North Chicago, Illinois
US

Company contact







Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.